Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026
STOCKHOLM, October 28, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the third quarter 2026, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 32.2...
Covered in this story
Call it yourself
No calls on $BIOA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Bioage Labs Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.